We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biological Markers Evaluated for Early Cervical Cancer Diagnosis

By LabMedica International staff writers
Posted on 27 Jun 2013
A method for the early diagnosis and prognosis of cervical cancer has been investigated which may lead to potential gene therapy biological targets. More...


The expression of the anti-oncogene phosphatase and tensin (PTEN) homologue and survivin in the progression of cervical neoplasia has been elucidated based on clinic-pathological features in squamous cell carcinoma of the uterine cervix.

Scientists at the Yangzhou University Medical College (China) enrolled for a study 20 patients with cervical ectropion and squamous metaplasia, 30 with cervical intraepithelial neoplasia, and 49 with cervical squamous cell carcinoma between January 2010 and August 2011. Normal cervical epithelium from 10 people served as the control. Immunohistochemical staining was performed to detect PTEN and survivin expression in each group using a streptavidin kit (Zhongshan Golden Bridge Biotechnology, Beijing, China).

The investigators found that PTEN expression progressively decreased with the continuum from normal epithelium to squamous cell carcinoma, whereas survivin expression progressively increased. Furthermore, positive PTEN immunostaining was associated with clinical stage and tumor size. The level of PTEN expression in the metastatic pelvic lymph node group was significantly lower compared with the nonmetastatic pelvic lymph node group. Positive survivin immunostaining was associated with clinical stage and tumor size. Survivin-positive expression in the metastatic pelvic lymph node group was significantly higher compared with the nonmetastatic pelvic lymph node group.

The PTEN gene acts as a tumor suppressor gene through the action of its phosphatase protein product, while survivin is a protein encoded by the antiapoptotic gene baculoviral inhibitor of apoptosis repeat containing 5 (BIRC5). The authors concluded that positive expression levels of PTEN and survivin provide potential evaluation indices for early diagnosis and prognosis of uterine cervical cancer, and these biomarkers are also potentially promising therapeutic targets. The study was published in the June 2013 online edition of the journal the British Journal of Biomedical Science.

Related Links:

Yangzhou University Medical College
Zhongshan Golden Bridge Biotechnology



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.